Tubach Florence, Ravaud Philippe, Beaton Dorcas, Boers Maarten, Bombardier Claire, Felson David T, van der Heijde Desireé, Wells George, Dougados Maxime
Département d'Epidémiologie, Biostatistique et Recherche Clinique, Hôpital Bichat, Paris, France.
J Rheumatol. 2007 May;34(5):1188-93.
The concepts of minimal clinically important improvement (MCII) and patient acceptable symptomatic state (PASS) could help in interpreting results of trials involving patient-reported outcomes by translating the response at the group level (change in mean scores) into more clinically meaningful information by addressing the patient level as "therapeutic success (yes/no)." The aims of the special interest group (SIG) at OMERACT 8 were to discuss specific issues concerning the MCII and PASS concepts, especially the wording of the external anchor questions used to determine the MCII and PASS estimates, and to move toward a consensus for the cutoff values to use as the MCII and PASS in the different outcome criteria. The purpose of this SIG at OMERACT 8 was to inform participants of the MCII and PASS concepts and to agree on MCII and PASS values for pain, patient global assessment, and functional impairment.
最小临床重要改善(MCII)和患者可接受症状状态(PASS)的概念有助于解释涉及患者报告结局的试验结果,通过将组水平的反应(平均得分变化)转化为更具临床意义的信息,即将患者水平视为“治疗成功(是/否)”。在骨关节炎研究学会(OMERACT)第8届会议上,特别兴趣小组(SIG)的目标是讨论与MCII和PASS概念相关的具体问题,尤其是用于确定MCII和PASS估计值的外部锚定问题的措辞,并就不同结局标准中用作MCII和PASS的临界值达成共识。OMERACT第8届会议上这个SIG的目的是让参与者了解MCII和PASS概念,并就疼痛、患者整体评估和功能损害的MCII和PASS值达成一致。